KIOVIG, BAXTER'S NEW IVIG PRODUCT RECEIVES UNANIMOUS POSITIVE OPINION IN EUROPE AS REPLACEMENT THERAPY FOR IMMUNODEFICIENCIES AND FOR IMMUNOMODULATION IN IMMUNE-MEDIATED DISEASES
Zurich (OTS) - Baxter Healthcare S.A. announced today that Baxter´s ready-to-use liquid 10% Intravenous Immunoglobulin (IVIG), has received unanimous positive opinion for marketing authorization from the Committee...
- 24.11.2005, 09:55:08
- /
- OTS0060 OTW0060